Key result
Regular haemodialysis treatment in ESRF patients aged 65-85 showed no significant differences in mortality or other parameters compared to patients aged 40-55, aside from higher morbidity.
Why the study?
Does regular haemodialysis treatment yield similar outcomes in ESRF patients aged 65-85 compared to those aged 40-55?
Cohort (n=52)
Does regular haemodialysis treatment yield similar outcomes in ESRF patients aged 65-85 compared to those aged 40-55?
Regular haemodialysis is a viable treatment for ESRF patients over 65, with outcomes largely comparable to younger patients despite higher morbidity.
Answers are grounded in this paper and cite their sources.
Comparable mortality on HD in ESRF patients aged 65-85 vs 40-55; leaves open selection bias in this observational cohort.
This manuscript consists of a study of the results of 26 end stage renal failure (ESRF) patients, who commenced regular haemodialysis treatment (RHDT) from the age of 65 onwards (65-85) and who have been undergoing this treatment for periods ranging from 7 years to 3 months. These results are to be compared with those obtained from another group of 26 patients whose age ranged between 40 and 55 and who were treated with the same policy. The following parameters are compared: mortality, morbidity, life-style, cardiovascular situation, hypotension in haemodialysis, vascular access, anaemia, osteoarticular and peripheral nervous disorders, hypertension. We have not found any significant differences between both groups, besides a higher morbidity for patients over 65. Therefore, we recommend the inclusion of the older patients into RHDT programmes.
No takes yet. Share an insight, caveat, or question.
Rotellar et al. (2008) conducted a cohort in End stage renal failure (ESRF) (n=52). Regular haemodialysis treatment (RHDT) from age 65 onwards vs. RHDT in patients aged 40-55 was evaluated on Mortality, morbidity, life-style, cardiovascular situation, hypotension, vascular access, anaemia, osteoarticular and peripheral nervous disorders, hypertension. Regular haemodialysis treatment in ESRF patients aged 65-85 showed no significant differences in mortality or other parameters compared to patients aged 40-55, aside from higher morbidity.
Synapse has enriched 10 related papers. Consider them for comparative context: